A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Antidepressants include SSRIs, SNRIs, tricyclics, MAOIs, and atypical agents, all targeting monoamine systems (serotonin, norepinephrine, dopamine). Despite mechanistic diversity, they show similar efficacy (~60% response rate) in MDD and anxiety disorders. They require 4-6 weeks for clinical effect; relapse risk is high upon discontinuation. Individual variation in response, side effects (sexual dysfunction, weight gain, activation), and drug interactions require individualized selection and monitoring.
From your study of monoamine synthesis and catabolism, you know that serotonin, norepinephrine, and dopamine are inactivated primarily by two mechanisms: reuptake via transporter proteins (SERT, NET, DAT) and enzymatic degradation by monoamine oxidase (MAO). Every major antidepressant class targets one or more points in this system. The diversity of drug classes reflects different historical discoveries—often accidental—rather than a principled hierarchy of treatments.
SSRIs (selective serotonin reuptake inhibitors: fluoxetine, sertraline, escitalopram) block SERT, increasing synaptic serotonin availability with minimal effects on other transporters or receptors. Their selectivity produces a cleaner side-effect profile than older drugs. SNRIs (venlafaxine, duloxetine) block both SERT and NET, adding noradrenergic effects and showing some efficacy in chronic pain conditions. Older tricyclic antidepressants (amitriptyline, imipramine) block multiple transporters plus muscarinic, histaminergic, and adrenergic receptors—broadening efficacy but producing anticholinergic side effects (dry mouth, constipation, cognitive blunting) and dangerous cardiac effects in overdose. MAOIs (phenelzine, tranylcypromine) prevent degradation of all three monoamines simultaneously, making them potent but requiring strict dietary restriction to avoid hypertensive crises from dietary tyramine.
The 4–6 week lag to clinical effect is among the most clinically important and theoretically puzzling features of antidepressants. Reuptake blockade begins within hours of the first dose—monoamine levels rise almost immediately—yet depressive symptoms persist for weeks. The leading explanation involves neuroadaptation: autoreceptors that initially blunt the effect of increased monoamine availability (by reducing neuron firing) gradually desensitize; downstream receptor expression, synaptic structure, and neuroplasticity markers like BDNF (brain-derived neurotrophic factor) require sustained elevated signaling over weeks before meaningful change accumulates. This lag explains why stopping medication too soon (before the response has fully developed) is a common reason for treatment failure.
Individual variation in treatment response is large, and its sources are still incompletely understood. A patient whose depression involves primarily serotonergic dysregulation may respond to an SSRI; one with noradrenergic or dopaminergic involvement may not. Genetic variants in CYP450 enzymes (CYP2D6, CYP2C19) determine how quickly patients metabolize many antidepressants, producing wildly different effective doses at the same prescription level. The ~60% response rate also means that for 40% of patients, the first-line medication does not work—treatment-resistant depression requires escalating strategies: medication switches, augmentation with atypical antipsychotics or lithium, combination pharmacotherapy, or non-pharmacological interventions like electroconvulsive therapy (ECT) or TMS.